Other substances

Nb11‐59

An anti-RBD (SARS-CoV-2 Spike) nanobody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Nb11-59 is a nanobody identified using a phage display technique based on its affinity for SARS-CoV-2 Spike protein RBD. The nanobody gene originated in a camelid immunized with RBD. It neutralizes SARS-CoV-2 in vitro and is stable after nebulisation (Gai et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential
Spike protein Biophysical assay In vitro Antibody 		in vitro binding assay; in vitro biophysical assay; ACE2/HEK293 cells; Vero E6 cells; SARS-CoV-2 live virus

The nanobody bound RBD and neutralized SARS-CoV-2 live virus in Vero E6 cells (with a 50% neutralization at 0.55 μg/ml). It was shown to be stable in a nebulised formulation and was efficiently produced in a Pichia pastoris system.

 Mar/04/2021
Export (.csv)